GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Total Stockholders Equity

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Total Stockholders Equity : HK$890 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Total Stockholders Equity?

Biocytogen Pharmaceuticals (Beijing) Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$890 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Biocytogen Pharmaceuticals (Beijing) Co's Book Value per Share for the quarter that ended in Dec. 2024 was HK$2.24. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.68.

Biocytogen Pharmaceuticals (Beijing) Co Total Stockholders Equity Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Total Stockholders Equity Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
1,722.92 1,527.17 1,280.05 859.59 890.50

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only 1,280.05 1,050.42 859.59 796.31 890.50

Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Biocytogen Pharmaceuticals (Beijing) Co's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(890.498-0)/396.889
=2.24

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(241.289 + 367.58) / 890.498
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Total Stockholders Equity
Comparable Companies
HKSE:02480 HKSE:01477 HKSE:02256 HKSE:06660 HKSE:02616 HKSE:02179 HKSE:02105 HKSE:06955 HKSE:01672 HKSE:01873 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
I54:Germany
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
Executives
Wei Ke Xiang Gang Jing Mao You Xian Gong Si 2101 Beneficial owner
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines